β-endorphin is a neuropeptide involved in several brain functions: its plasma levels are higher in obese women and its release increases after oral glucose tolerance test (OGTT) in normal or obese women. The study included 46 healthy women and evaluated the effect of oral dehydroepiandrosterone [DHEA] (50 mg/day) in early postmenopausal women (50–55 years) both of normal weight (group A, n = 12, BMI = 22.1 ± 0.5) and overweight (group B, n = 12, BMI = 28.2 ± 0.5), and late postmenopausal women (60–65 years) both normal weight (group C, n = 11, BMI = 22.5 ± 0.6) and overweight (group D, n = 11, BMI = 27.9 ± 0.4) undergone OGTT, in order to investigate if DHEA could restore/modify the control of insulin and glucose secretion and β-endorphin release in response to glucose load. The area under the curve (AUC) of OGTT evaluated plasma levels of different molecules. DHEA, DHEAS, and β-endorphin plasma levels were lower in baseline conditions in older women than younger women. Considering the AUC of β-endorphin response to OGTT, all groups showed a progressive significant increase after 3 and also after 6 months of treatment in comparison to baseline and 3 months of treatment.

Oral dehydroepiandrosterone restores β-endorphin response to OGTT in early and late postmenopause

Giannini, A.
Primo
Writing – Original Draft Preparation
;
Genazzani, A. D.
Secondo
Conceptualization
;
Caretto, M.
Data Curation
;
Simoncini, T.
Penultimo
Supervision
;
Genazzani, A. R.
Ultimo
Writing – Review & Editing
2019-01-01

Abstract

β-endorphin is a neuropeptide involved in several brain functions: its plasma levels are higher in obese women and its release increases after oral glucose tolerance test (OGTT) in normal or obese women. The study included 46 healthy women and evaluated the effect of oral dehydroepiandrosterone [DHEA] (50 mg/day) in early postmenopausal women (50–55 years) both of normal weight (group A, n = 12, BMI = 22.1 ± 0.5) and overweight (group B, n = 12, BMI = 28.2 ± 0.5), and late postmenopausal women (60–65 years) both normal weight (group C, n = 11, BMI = 22.5 ± 0.6) and overweight (group D, n = 11, BMI = 27.9 ± 0.4) undergone OGTT, in order to investigate if DHEA could restore/modify the control of insulin and glucose secretion and β-endorphin release in response to glucose load. The area under the curve (AUC) of OGTT evaluated plasma levels of different molecules. DHEA, DHEAS, and β-endorphin plasma levels were lower in baseline conditions in older women than younger women. Considering the AUC of β-endorphin response to OGTT, all groups showed a progressive significant increase after 3 and also after 6 months of treatment in comparison to baseline and 3 months of treatment.
2019
Giannini, A.; Genazzani, A. D.; Napolitano, A.; Caretto, M.; Stomati, M.; Simoncini, T.; Genazzani, A. R.
File in questo prodotto:
File Dimensione Formato  
Giannini et al. 2018-0699.R2.docx

Open Access dal 01/10/2020

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 49.57 kB
Formato Microsoft Word XML
49.57 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/987110
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact